[ET Net News Agency, 3 June 2021] Sino Biopharmaceutical Limited (01177) said
"Linezolid and Glucose Injection" (brand name: Tianli), an antibacterial drug developed by
the group, has obtained the notice of approval of supplemental application on
pharmaceutical product issued by the National Medical Products Administration of the
People's Republic of China, and passed the Consistency of Quality and Efficacy Evaluation
for Generic Drugs (consistency evaluation).
Linezolid is used to cure the following infections caused by specific strains of
susceptible microorganisms: hospital-acquired pneumonia, community-acquired pneumonia,
complicated skin and soft tissue infections, uncomplicated skin and soft tissue
infections, and vancomycin-resistant enterococcus faecium infection. (RC)
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Outstanding Qty | % Implied Volatility
22739 SG-HKEX@EP2412A (PUT)
Nominal 
0.100 +0.005 (+5.263%) 03/06/2021 15:17
Sino Biopharm (01177) drug passes consistency evaluation
| Remark: | Real time quote last updated: 30/04/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |